Palisade Bio, Inc.

Equities

SNCA

US6963894026

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 09:35:21 17/07/2024 pm IST			5-day change	1st Jan Change
4.27 ^USD	-3.50%		-4.47%	-51.75%

11/07	Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product	CI
21/06	Palisade Bio Provides Update on Advancement of Its Strategic Collaboration with Strand Life Sciences	CI

Neuralstem Appoints Catherine Angell Sohn to Board of Directors

January 14, 2014 at 07:31 pm IST

Neuralstem, Inc. announced the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board of Directors, bringing the total number of board members to six. Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline.

Latest news about Palisade Bio, Inc.

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product	11/07	CI
Palisade Bio Provides Update on Advancement of Its Strategic Collaboration with Strand Life Sciences	21/06	CI
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108	11/06	CI
Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108	21/05	CI
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Palisade Bio, Inc. announced that it has received $3.999943 million in funding	10/05	CI
Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	07/05	CI
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	01/05	MT
Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	01/05	CI
Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding	01/05	CI
Palisade Bio Collaborating With Strand Life Sciences on Ulcerative Colitis Therapy	23/04	MT
Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23/04	CI
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	16/04	MT
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	16/04	MT
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	16/04	CI
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Palisade Bio, Inc. Announces Resignation of Mary Ann Gray as Member of the Board	07/03	CI
Palisade Bio Names Donald Williams as Chairman	13/02	MT
Palisade Bio, Inc. Announces Advisory Board Appointments	09/02	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	30/01	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	30/01	MT
Top Midday Gainers	30/01	MT
Palisade Bio's Shares Climb Following Preclinical Data on Ulcerative Colitis Drug Candidate	29/01	MT
Palisade Bio Says Giiant Pharma Receives Second Milestone Payment for PALI-2108 Development	28/12	MT

Chart Palisade Bio, Inc.

Duration

Period

More charts

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

Sector

Biotechnology & Medical Research

Calendar

20/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.425 USD

Average target price

33.75 USD

Spread / Average Target

+662.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PALISADE BIO, INC.	-51.75%	41.44L
MODERNA, INC.	+23.59%	4.8TCr
IQVIA HOLDINGS INC.	+0.11%	4.24TCr
LONZA GROUP AG	+43.96%	4.15TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.91%	3.16TCr
ICON PUBLIC LIMITED COMPANY	+19.44%	2.86TCr
CELLTRION, INC.	-4.47%	2.8TCr
UNITED THERAPEUTICS CORPORATION	+51.34%	1.46TCr
MEDPACE HOLDINGS, INC.	+43.72%	1.41TCr
BIO-TECHNE CORPORATION	+2.03%	1.26TCr

Other Biotechnology & Medical Research